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ABSTRACT 
The interaction of multiple myeloma (MM) cells with the bone marrow (BM) 
microenvironment promotes MM cell retention, survival and resistance to different anti-MM 
agents, including proteasome inhibitors (PIs) such as bortezomib (BTZ). The α4β1 integrin is a 
main adhesion receptor mediating MM cell-stroma interactions and MM cell survival, and its 
expression and function are downregulated by BTZ, leading to inhibition of cell adhesion-
mediated drug resistance (CAM-DR) and MM cell apoptosis. Whether decreased α4β1 
expression and activity is maintained or recovered upon development of resistance to BTZ 
represents an important question, as a potential rescue of α4β1 function could boost MM cell 
survival and disease progression. Using BTZ-resistant MM cells, we found that they not only 
rescue their α4β1 expression, but its levels were higher than in parental cells. Increased α4β1 
expression in resistant cells correlated with enhanced α4β1-mediated cell lodging in the BM, 
and with disease progression. BTZ-resistant MM cells displayed enhanced NF-κB pathway 
activation relative to parental counterparts, which contributed to upregulated α4 expression and 
to α4β1-dependent MM cell adhesion. These data emphasize the upregulation of α4β1 
expression and function as a key event during resistance to BTZ in MM, which might indirectly 
contribute to stabilize this resistance, as stronger MM cell attachment to BM stroma will regain 
CAM-DR and MM cell growth and survival. Finally, we found a strong correlation between 
high ITGB1 (integrin β1) expression in MM and poor progression-free survival (PFS) and 
overall survival (OS) during treatment of MM patients with BTZ and IMIDs, and combination 
of high ITGB1 levels and presence of the high-risk genetic factor amp1q causes low PFS and 
OS. These results unravel a novel prognostic value for ITGB1 in myeloma.  
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INTRODUCTION 
Multiple myeloma is a hematological neoplasia characterized by clonal expansion of 
antibody-producing malignant plasma cells in the bone marrow (BM), causing osteolytic bone 
lesions, hypercalcemia, anemia and renal failure [1-5]. In spite that different treatments against 
MM including autologous stem cell transplantation, proteasome inhibitors, immunomodulatory 
drugs, chimeric antigen receptor (CAR) T cell and monoclonal antibody therapies have 
improved patient survival [6–10], the disease remains largely incurable.  
The communication of MM cells with their surrounding BM microenvironment depends 
on specific adhesion receptor-ligand interactions, and is critical for MM cell localization and 
retention, for survival, and for resistance to chemotherapy [1,4]. MM cell trafficking to and 
inside the BM is based on the activity of the α4β1 (also called VLA-4) integrin [11–13]. A 
functional partner of α4β1 is CXCL12, an abundant chemokine in the BM, which upon binding 
to its receptor CXCR4 delivers stimulating signals for upregulation of α4β1-mediated MM cell 
adhesion [14–16]. The attachment of MM cells mediated by α4β1 to its ligands VCAM-1 and 
fibronectin, both present in the myeloma BM compartment, does not only provide MM cell 
localization, but it also contributes to cell survival and to cell adhesion-mediated drug resistance 
(CAM-DR). Thus, early studies revealed that α4β1-dependent MM cell adhesion to BM stromal 
cells induces IL-6 secretion, a key cytokine for MM cell proliferation and survival, and in vivo 
approaches demonstrated the importance of α4β1-mediated MM cell attachment for disease 
progression [17–19]. Furthermore, the humanized anti-α4 monoclonal antibody natalizumab 
was shown to decrease MM cell growth in the BM microenvironment [20]. The relevance of 
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α4β1 in promoting CAM-DR has been revealed in MM cells exposed to melphalan, 
doxorubicin, bortezomib (BTZ) and simvastin [21–23].  
Proteasome inhibitors (PIs) represent common agents used against MM [6,24,25]. All 
approved PIs target the PSMβ5 subunit of the proteasome, including BTZ, carfilzomib (CFZ) 
and ixazomib [25]. Mutations in this subunit causing failure of BTZ binding to the proteasome 
represent a potential mechanism of MM cell resistance to this inhibitor [26-29]. Other reported 
mechanisms of resistance to PIs include clearance of misfolded proteins by autophagic 
elimination of aggresomes, aberrant NF-κB pathway activation, metabolic dysregulation, and 
involvement of the BM microenvironment [25,28]. Therefore, there is no a single primary 
mechanism absolutely responsible for providing resistance to PI in MM cells, which is an 
important clinical problem. Moreover, resistance to PIs might involve indirect cell responses 
directly impinging on primary resistance mechanisms.  
BTZ can overcome CAM-DR by downregulating α4β1 expression in MM cells [23]. 
Similarly, a modulation by BTZ of the α4β1/VCAM-1 interaction involving hematopoietic stem 
and progenitor cell adhesion to the BM microenvironment was also reported [30]. Given the key 
role of α4β1 in MM disease progression, its downregulation in BTZ-exposed MM cells could 
affect their BM trafficking, retention and survival. However, whether the decreased α4β1 
expression and function is maintained or recovered upon development of resistance to BTZ 
represents an important question which has not been addressed. A potential rescue of α4β1 
expression and function could clearly affect the outcome of the disease. Here we have generated 
BTZ-resistant MM cells to uncover potential relationships between α4β1 expression and 
function and resistance to BTZ. Our data provide in vitro and in vivo evidence of rescue of high 
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α4β1 expression and activity in BTZ-resistant MM cells, highlighting a potential α4β1 role as 
indirect contributor of resistance to PIs. In addition, we have unveiled a prognostic value for 
ITGB1 (integrin β1) expression combined with genetic biomarkers during MM treatment with 
therapies that include BTZ.    
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 MATERIALS AND METHODS 
 
Details for Cells, reagents and antibodies used, Flow cytometry, apoptosis and VCAM-1 
binding assays, RNA interference, transfections and RT-qPCR are presented in Supplementary 
material, Supplementary materials and methods. 
 
Cell proliferation and adhesion assays. A tetrazolium salt was used to estimate cell 
proliferation, according to manufacturer’s instructions (CCK-8 kit, Sigma-Aldrich, St. Louis, 
MO, USA). In brief, cells were tested in triplicated, and after 2 h at 37 °C with CCK-8 solution, 
sample Absorbance was read at 450 nm (Multiskan Bichromatic, Labsystems, Vantaa, Finland). 
Assays of adhesion to α4β1 ligands were carried out as we described previously [31]. In brief, 
BCECF-AM-labeled cells were plated in triplicate in wells coated with the fibronectin 
recombinant fragment FN-H89 (CS-1/FN), that contains the α4β1-binding CS-1 region, or with 
recombinant VCAM-1, in the absence or presence of immobilized CXCL12. Plates were 
incubated for 2 min at 37 °C after a brief centrifugation (2 s, 1,200 rpm), and adhesion 
quantified using a fluorescence analyzer. Adhesion data is presented relative to control cells, 
which were given an arbitrary value of 100.  
 
Immunoblotting. Cells were solubilized in lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl pH 
7.4, 100 mM NaCl, 2 mM MgCl2, 10% glycerol) in the presence of protease and phosphatase 
inhibitors (Sigma Aldrich). Proteins were resolved by SDS-PAGE, transferred to PVDF 
membranes (Bio-Rad Laboratories, Hercules, CA, USA) and incubated with primary antibodies 
and horseradish peroxidase-conjugated secondary antibodies listed in supplementary material, 
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Table S2. Proteins were visualized using Immobilon Western (Millipore, Billerica, MA, USA) 
and a chemiluminescence detector (Fujifilm LAS 3000 Image Reader, Fujifilm, Tokyo, Japan).  
 
In vivo studies. The Consejo Superior de Investigaciones Científicas Ethics Committee 
approved the protocols used for experiments with mice. NOD/SCID/IL2gR-/- (NSG) mice were 
subcutaneously inoculated with 1.5×106 parental or BTZ-resistant NCI-H929 cells. When 
tumors were visually detected (around day 6), mice were randomly divided into two groups and 
intraperitoneally (i.p.) injected every 2 or 3 days with BTZ (0.8 mg/kg in PBS) or vehicle 
(DMSO in PBS), and tumor growth was monitored daily. RPMI-8226 and RPMI-8226-R7 cells 
were pre-incubated for 20 min at 37 °C with control (P3) or anti-α4 (ALC 1.63) antibodies (50 
µg/ml) before inoculation into NSG mice (n=7-–9 per cell type). Cells (3x106) from the different 
groups were intravenously injected into the tail vein and were treated i.p. every 2-3 days with 
control or anti-α4 (300 µg/kg) antibodies. After approximately 4 weeks, mice injected with 
RPMI-8226-R7 cells and receiving control antibodies displayed hind limb paralysis, and then 
mice from all groups were sacrificed. MM cell infiltration in the BM of femurs was evaluated by 
flow cytometry (FACS) for expression of human HLA-1, and by RT-qPCR to determine human 
GAPDH versus mouse Tbp expression. 
 
Survival studies. For survival analyses, we used the survival data from the IA14 release of the 
Multiple Myeloma Research Foundation (MMRF) CoMMpass Study dataset. In the 
progression-free survival (PFS) and overall survival (OS), we included 285 MM patients treated 
with bortezomib and immunomudulatory drugs (IMIDs). CoMMpass RNA-seq samples were 
processed with Salmon v0.9.1 using Gencode v27. We used the maxStat package (R) to select a 
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threshold value for the expression of the ITGA4, ITGB1 and CXCR4 genes. In order to avoid the 
bias introduced by this package, the threshold was selected as the median of 50,000 possible 
thresholds calculated with one third of the samples, randomly but balanced-selected. Using the 
threshold, we discretized the genes as lowly or highly expressed, and then performed univariate 
COX regressions. We searched the synergy with biomarkers published in IA14, selected and 
filtered using LogRank single variable regression performing a Monte Carlo simulation provided 
by maxStat, selecting only those variables with significant p-value. These variables were 
included in a multivariate cox regression in order to select the ones that remained significant. 
 
Statistical analysis. Analyses were performed with GraphPad Prism 5. Outliers according to 
Grubbs' test were excluded. Two groups of normally-distributed data were compared using 
paired or unpaired t-tests. Results were considered significantly different when p<0.05. Values 
at *p<0.05, **p< 0.01, and ***p<0.001, denoted a significant decrease, whereas ∆p<0.05, ∆∆p< 
0.01, and ∆∆∆p<0.001 indicated a significant increase.  
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RESULTS 
Characterization of bortezomib-resistant myeloma cells. Two independent NCI-H929 
myeloma cell cultures were exposed to gradual increases of BTZ concentrations, from 5 nM to 
20 nM. When cells were with 20 nM BTZ in normal culture medium, cultures displayed a short 
quiescent period without apparent growth, which was surpassed by increasing FBS to 20% and 
adding IL-6. Once cells were back to normal proliferation rates, serum was decreased to 10% 
and IL-6 removed without affecting growth. Cell proliferation assays revealed that, compared to 
the strong growth inhibition of parental cells treated with BTZ, the two BTZ-resistant cell 
cultures, NCI-H929-R20.1 and NCI-H929-R20.2 display growth rates in the presence of BTZ 
similar to parental ones, although the R20.2 cells showed a slower rate (Figure 1A). We also 
obtained NCI-H929 cells continuously growing in BTZ 35 nM (NCI-H929-R35; see 
supplementary material, Figure S1A, left), although their proliferation was slower than that of 
R20 cells, what led us to use the later for the subsequent studies. NCI-H929-R20.1 cells not only 
proliferated in the presence of BTZ, but they were also resistant to carfilzomib (CFZ) (Figure 
1B), suggesting that they might present general resistance to PIs. Growth inhibition of NCI-
H929 cells by BTZ or CFZ was associated with apoptosis, while NCI-H929-R20.1 and NCI-
H929-R35 cells incubated with these PIs exhibited no significant increase in apoptosis relative 
to non-treated cells (Figure 1C; see supplementary material, Figure S1A, right). NCI-H929-
R20.1 cell resistance to BTZ was next tested in vivo in NSG mice. When subcutaneous tumors 
were evident, we treated mice with BTZ or vehicle, and periodically measured tumor volumes. 
Data revealed that NCI-H929-R20 cells generated faster and larger tumors than parental 
counterparts in vehicle-treated mice (Figure 1D). Whereas BTZ significantly inhibited NCI-
H929 tumor growth, NCI-H929-R20 tumors displayed similar volumes at the end of the 
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experiment independently of treatment with BTZ or vehicle. These in vivo results confirm the 
resistance to BTZ of NCI-H929-R20 cells. 
 Further characterization of NCI-H929-R20 cells revealed full sensitivity to the anti-MM 
drugs Aplidin (plitidepsin) (see supplementary material, Figure S1B) and doxorubicin (not 
shown). To determine if resistance could involve drug extrusion by the ABC-family P-
glycoprotein (PgP), we first performed FACS to compare PgP expression on NCI-H929 and 
NCI-H929-R20 cells. The results revealed that neither parental nor resistant cells expressed PgP, 
as compared with PgP-transfected LoVo cells used as positive controls (see supplementary 
material, Figure S1C). Moreover, when we combined BTZ and the PgP inhibitor verapamil [32], 
there was only a minor reduction (10%) in cell viability relative to BTZ treatment alone (see 
supplementary material, Figure S1D), indicating that resistance to BTZ was mostly independent 
of PgP activity.    
 As expected, parental NCI-H929 cells exposed to BTZ displayed accumulation of 
ubiquitinated proteins, indicating that the PI was inhibiting the proteasome (Figure 1E). 
Incubation of NCI-H929-R20 cells with BTZ also caused accumulation of ubiquitinated proteins 
but to a lesser extent than parental cells. Mutations on the PSMB5 subunit of the proteasome 
have been implicated in resistance to BTZ [26,27]. Sequencing PSMB5 revealed no mutations 
on NCI-H929-R20 cells (not shown), but RT-qPCR analyses showed that these cells have higher 
PSMB5 levels than parental counterparts (Figure 1F), similar to previous observations in BTZ-
resistant cells [33].  
Bortezomib-resistant MM cells display higher α4β1 expression and function than parental 
cells. Analyses by qPCR of BTZ-treated primary CD138+ MM bone marrow cells revealed a 
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remarkable decrease in ITGA4 and ITGB1 expression (Figure 2A). We found that this reduced 
expression was independent of disease stage, type (IgG or IgA kappa), degree of BM plasma 
cell infiltration, and the age and sex of patients. Similar to CD138+ cells, BTZ-exposed parental 
NCI-H929 cells displayed a strong reduction in cell membrane α4 and β1 expression, whereas 
CXCR4 and integrin α5 expression decreased only moderately (Figure 2B, left). Of note, NCI-
H929-R20.1 and -R20.2 cells displayed membrane expression levels of α4, β1 and α5 that were 
significantly higher than those of parental cells (Figure 2B, left and right; see supplementary 
material, Figure S1E). Instead, CXCR4 expression remained mostly unaltered. Consistent with 
the higher cell membrane expression of α4β1 in NCI-H929-R20 cells, immunoblotting assays 
showed increased α4 and β1 levels in these cells relative to parental cells (Figure 2C; see 
supplementary material, Figure S1F), which correlated with enhanced ITGA4 and ITGB1 levels 
(Figure 2D). In spite of the unchanged CXCR4 membrane expression on NCI-H929-R20 cells, 
we found higher CXCR4 levels in these resistant cells than in parental ones (Figure 2D). 
Although both NCI-H929-R20.1 and NCI-H929-R20.2 cells exhibited upregulation of α4β1 
expression, as the R20.1 cells grew better in culture than the R20.2 counterparts, we selected the 
former to functionally characterize BTZ-resistant MM cells in α4β1-dependent adhesion assays. 
In close correlation with upregulated α4β1 expression on NCI-H929-R20 cells, they displayed 
increased adhesion to the α4β1 ligands VCAM-1 and CS-1/FN, both in the absence and 
presence of co-immobilized CXCL12 (Figure 2E). Moreover, soluble VCAM-1 binding was 
higher on the BTZ-resistant than on the parental cells (Figure 2F).  
 To determine if upregulation of α4β1 expression seen on NCI-H929-R20 cells could also 
be detected in other MM cell lines, we used the previously reported BTZ-resistant RPMI-8226-
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R7 and RPMI-8226-R100 cells [27]. These cells display upregulation of mutant PSMB5 
proteasome subunit that affects BTZ binding, causing resistance to this inhibitor. In line with 
these observations, we found no accumulation of ubiquitinated proteins in BTZ-treated RPMI-
8226-R7 and RPMI-8226-R100 cells compared to parental cells (see supplementary material, 
Figure S2A).  
Analogous to the NCI-H929 parental-resistant cell pair, FACS experiments revealed that 
both RPMI-8226-R7 and RPMI-8226-R100 cells have higher α4β1 expression than parental 
cells (Figure 3A). Unlike NCI-H929-R20 cells, BTZ-resistant RPMI-8226 cells displayed 
enhanced CXCR4 membrane expression, whereas α5 integrin levels were reduced. Consistent 
with the FACS data, immunoblotting analyses showed that α4 and β1 expression was 
upregulated in resistant RPMI-8226 cells (Figure 3B). In addition, both RPMI-8226-R7 and 
RPMI-8226-R100 cells cultured for 3 weeks without the PI retained resistance to BTZ (see 
supplementary material, Figure S2B) and higher α4 and β1 levels than parental cells (Figure 
3C), indicating that resistance and increased α4β1 expression were independent of the 
continuous cell exposure to BTZ.  
The expression of ITGA4 and CXCR4 was significantly higher in BTZ-resistant RPMI-
8226 than parental cells (Figure 3D), correlating with their enhanced protein levels, whereas 
ITGB1 expression was elevated in RPMI-8226-R100 but not in RPMI-8226-R7 cells (Figure 
3D). These results indicated that upregulated α4 expression in NCI-H929 and RPMI-8226 
resistant cells is at least transcriptionally-based. To determine if increased β1 protein expression 
involved its stabilization, we treated RPMI-8226-R7 and RPMI-8226-R100 cells with 
cycloheximide and analyzed β1 levels by immunoblotting. The results revealed reduced β1 
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expression in cycloheximide-treated parental cells, whereas β1 accumulated in resistant cells 
exposed to cycloheximide (Figure 3E), indicating that increased β1 stability in resistant RPMI-
8226 cells represents one of the mechanisms responsible for its upregulation.    
 Next, we tested BTZ-resistant RPMI-8226 cells in adhesion assays to α4β1 ligands co-
immobilized with CXCL12, as they express elevated CXCR4 membrane levels. The results 
revealed significantly higher α4β1-mediated adhesion of RPMI-8226-R7 cells than parental 
counterparts (Figure 4A). Importantly, these resistant cells displayed a remarkable increase in 
lodging to the BM of NSG mice associated with hind limb paralysis relative to parental cells, as 
detected by specific human HLA-1+ expression. Notably, the upregulated resistant cell 
infiltration was blocked by anti-α4 antibodies, indicating the involvement of α4β1 in cell 
lodging in the BM (Figure 4B, left). Examination of the infiltrated MM cells from the BM 
indicated that resistant cells retained higher α4 expression than the parental cells (Figure 4B, 
right). Moreover, qPCR analyses of human GAPDH versus mouse TBP expression further 
supported the increased α4β1-dependent RPMI-8226-R7 cell lodging in the BM compared to 
parental cells (Figure 4C).  
BTZ-resistant MCL and T-ALL cells do not display upregulated α4β1 expression and 
function. Mantle cell lymphoma (MCL) is another hematological malignancy which can be 
treated with BTZ [34]. We generated BTZ-resistant Z-138 cells (Z-138-R10; resistant to 10 nM 
BTZ), as a model for MCL (see supplementary material, Figure S3A) to look for potential 
changes in α4β1 expression. Contrary to BTZ-resistant MM cells, FACS and immunoblotting 
analyses revealed no increased α4, β1 and CXCR4 expression in Z-138-R10 cells relative to 
untreated parental ones (see supplementary material, Figures S3B, S3C). Consistently, we did 
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not find significant variations between α4β1-dependent Z-138 and Z-138-R10 cell adhesion 
levels (see supplementary material, Figure S3D). T cell acute lymphoblastic leukemia (T-ALL) 
cells have been also found to be sensitive to BTZ [35]. We obtained BTZ-resistant Molt-4 cells 
(Molt-4-R7; resistant to 7 nM BTZ) as a T-ALL model (see supplementary material, Figure 
S3E). These cells displayed downregulated α4 and CXCR4 expression relative to parental 
counterparts, whereas the cell membrane β1 levels were enhanced both in parental and Molt-4-
R7 cells following BTZ treatment (see supplementary material, Figure S3F). Yet, no significant 
changes between α4β1-mediated parental and BTZ-resistant Molt-4 cell adhesion were detected 
(see supplementary material, Figure S3G). These results suggest that the enhanced α4β1 
expression and function seen in BTZ-resistant MM cells cannot be generalized to MCL and T-
ALL neoplasms.   
Role of NF-κB in the upregulated α4β1 expression on BTZ-resistant MM cells. Aberrant 
activation of the NF-κB pathway is frequent during MM progression and in BTZ-resistant MM 
cells [36-41]. Phosphorylation of p65 NF-κB at Ser536 is associated with transcriptional activity 
[42-45]. BTZ treatment of NCI-H929 and RPMI-8226-R7 cells upregulated phosphorylation at 
Ser536 p65, and the increased phosphorylation remained higher in BTZ-resistant than in 
untreated parental cells (Figure 5A), revealing the activation of the canonical NF-κB pathway in 
the resistant cells. Correlating with NF-κB pathway activation, the expression of two NF-κB 
targets, BIRC5 (also called Survivin) and HIF1A according to Hugo  [46–49] was significantly 
enhanced in the resistant cells compared to parental ones (Figure 5B). Of note, interfering with 
NF-κB activation in NCI-H929-R20.1 cells with the IKK inhibitor BAY-11-7082 significantly 
downregulated the expression of BIRC5, and also reduced ITGA4 levels, while ITGB1 
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expression was mostly unaltered (Figure 5C). Moreover, NF-κB1 silencing correlated with a 
significant decrease in ITGA4 and α4 cell membrane levels (Figure 5D, 5E, left), further 
suggesting a NF-κB role in the regulation of α4 expression in the resistant cells. Reduced α4 
surface expression correlated with a moderate decrease in NCI-H929-R20.1 cell attachment to 
CS-1/FN, although without reaching statistical significance (Figure 5E, right). These results 
suggest an involvement of NF-κB in the upregulated expression of α4β1 in BTZ-resistant MM 
cells.   
Prognostic value of ITGB1 in MM treatment with BTZ. To assess whether expression levels 
of ITGA4, ITGB1 or CXCR4 could correlate with the prognosis of MM patients exposed to 
therapies that include BTZ, we analyzed the progression-free survival (PFS) and overall survival 
(OS) of patients in the MMRF CoMMpass study during treatment with BTZ and IMIDs. These 
analyses were performed, according to the expression levels of each gene, and separating cases 
into two groups based on the distribution of expression levels. Whereas the expression levels of 
ITGA4 and CXCR4 at diagnosis did not correlate with prognosis, high ITGB1 expression was 
significantly associated with lower PFS and OS in MM patients included in the BTZ-IMIDs 
treatment (Figure 6A,B). When a multivariate analysis was performed combining the expression 
of other known high-risk genetic factors, the combination of high ITGB1 expression with amp1q 
resulted in statistically significant decrease in PFS and OS (Figure 6C,D). When these 2 
prognostic factors were combined, MM patients could be stratified into four groups with 
significant differences in PFS and OS (Figure 6E,F). These results demonstrate that combination 
of ITGB1 expression with established genetic biomarkers could have an important impact in 
prognosis of MM patients during the treatment with BTZ-IMIDs.  
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DISCUSSION 
Natural and acquired resistance to PIs represents a serious clinical challenge in MM 
treatment [25,28]. The interaction of MM cells with their surrounding BM microenvironment 
provides CAM-DR to PIs as well as to other anti-MM agents [21,22]. The α4β1 integrin is a 
main adhesion receptor involved in MM cell-stroma interactions and MM cell survival 
[12,17,19,20], and plays key roles in CAM-DR [11-13].  
Bortezomib downregulates the expression of α4β1 in MM cell lines, leading to 
inhibition of CAM-DR [22,23]. Likewise, we show here that BTZ treatment of CD138+-selected 
BM cells from MM patients resulted in decreased ITGA4 and ITGB1 expression, and we 
confirm that this treatment reduces α4β1 myeloma cell membrane levels. Using BTZ-resistant 
NCI-H929 and RPMI-8226 cells, we found that they not only autonomously rescue their α4β1 
expression upon development of resistance, but the integrin levels became higher than those of 
parental cells. Increased α4β1 expression had important functional consequences, as α4β1-
mediated MM cell attachment to VCAM-1 and fibronectin was higher in resistant than in 
parental cells. Moreover, we show by two different parameters that BTZ-resistant RPMI-8226 
cells have an increased α4β1-dependent capacity to lodge in the BM of NSG mice and to 
promote disease progression, as compared to parental cells. The enhanced BM lodging of the 
resistant cells mediated by α4β1 is likely contributed by their upregulated CXCR4 expression. 
Accordingly, the interaction between myeloma cell CXCR4 and CXCL12 present in the BM 
will likely increase α4β1 activity on resistant MM cells, facilitating their BM lodging. Of note, 
chemoresistant minimal residual disease (MRD) MM clones, including those resistant to BTZ, 
were enriched in cells overexpressing α4β1 relative to diagnostic clonal cells from MM patients 
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[50]. Together with our results, these data highlight the upregulation of α4β1 expression and 
function as an important and unwanted event which might indirectly contribute to 
chemoresistance to BTZ in MM. Thus, increased α4β1 expression could facilitate renewed and 
stronger MM cell attachment and retention by BM stroma, regaining the CAM-DR and favoring 
MM cell growth and survival. In addition, the data suggest that the enhanced α4β1 expression in 
BTZ-resistant MM cells could facilitate early identification of BTZ-treated patients developing 
resistance. Upregulated α4β1 levels were also reported in RPMI-8226 cells resistant to 
melphalan and doxorubicin [21], and increased expression of β1 integrin in BM cells from MM 
patients treated with melphalan-based regimens was found relative to pre-treatment [51], 
indicating that increased α4β1 expression might represent a common response during 
progression to resistance to different MM treatments.  
We found that the increased expression of the α4 subunit in BTZ-resistant MM cells has 
at least a transcriptional basis, although we cannot rule out that post-transcriptional events could 
also facilitate the α4 upregulation. Likewise, the enhanced β1 expression has a clear 
transcriptional basis in NCI-H929-R20 cells, and a tendency in RPMI-8226-R7 cells. Data from 
cycloheximide-exposed BTZ-resistant RPMI-8226 cells revealed that increased β1 expression is 
facilitated by its higher stability, likely contributing to upregulated cell adhesion. Similar to 
previous data [37,41], we found higher activation of the NF-κB pathway in the BTZ-resistant 
MM cells than in the parental counterparts. Moreover, using both an inhibitor of IKK that 
inactivates NF-κB, and siRNA-mediated NF-κB silencing, we show that increased NF-κB 
pathway activation in NCI-H929-R20 cells contribute to the upregulated ITGA4 expression, 
leading to increased α4 cell membrane levels. It is noteworthy that NF-κB depletion only 
This article is protected by copyright. All rights reserved.
  
partially decreased α4 cell membrane expression, which correlated with a moderate reduction in 
α4β1-dependent MM cell adhesion, indicating that other unidentified factors are also involved 
in the upregulated α4 expression and function in BTZ-resistant MM cells. Unlike ITGA4, IKK 
inhibition did not alter ITGB1 levels, suggesting that upregulation of ITGB1 expression in NCI-
H929-R20 cells is independent of NF-κB pathway activation.  
Increased CXCR4 membrane expression was also observed in BTZ-resistant RPMI-8226 
cells, but not on NCI-H929-R20 cells. Enhanced cell membrane CXCR4 levels have also been 
noted in myeloma MRD [50], although reduced CXCR4 expression was reported in mouse MM 
cells resistant to BTZ and in BTZ-treated MM patients [52]. Thus, further work is needed to 
unravel the cellular and molecular basis regulating CXCR4 expression in MM cells exposed to 
BTZ.  
The molecular mechanisms accounting for resistance in NCI-H929-R20 cells have not 
been addressed in the present study. Mutations on PSBM5 affecting BTZ binding proteasome, as 
well as overexpression of the β5 proteasome subunit were previously reported to mediate 
acquired resistance to BTZ in RPMI-8226 cells [26,27]. Although we did not detect mutations 
on PSBM5 in NCI-H929-R20 cells, the reduced accumulation of ubiquitinated proteins in these 
cells relative to parental cells suggest some disfunction in their proteasomes, which might 
include decreased BTZ binding to proteasomes. Similar to the present data, previous studies 
showed no mutations on PSBM5 in BTZ-resistant MM cells [53]. We did observe upregulated 
PSBM5 expression in NCI-H929-R20 cells, which might contribute to BTZ resistance. 
Finally, we found a significant correlation between high ITGB1 expression in MM cells 
from patients at diagnosis and poor PFS and OS following treatment with BTZ and IMIDs. 
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Furthermore, combination of high ITGB1 expression and presence of the high-risk genetic factor 
amp1q causes low PFS and OS, therefore unraveling a novel prognostic value for ITGB1 in 
these MM patients and suggesting that high β1 expression might identify MM patients with high 
risk of disease progression.  
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FIGURE LEGENDS 
Figure 1. Characterization of bortezomib-resistant NCI-H929 cells. Parental and BTZ-
resistant cells were treated for the indicated times without or with BTZ (20 nM) (A), or for 48 h 
with CFZ (40 nM) (B), and subsequently subjected to proliferation assays with CCK8 (n=3 or 
4). Proliferation was reduced ***p<0.001, or augmented ∆∆∆p<0.001). (C) Cells were incubated 
for 48 h with BTZ or CFZ (20 and 40 nM, respectively), and the apoptotic rates determined by 
flow cytometry (n=3). (D) Parental and BTZ-resistant NCI-H929 cells were subcutaneously 
inoculated into NSG mice, and when tumors started to grow, mice were treated with either 
DMSO (Ctrl) or BTZ in DMSO. Shown are tumor volumes at different time points (n=5-8; 
*p<0.05). (E) Cells were treated for the indicated times without (-) or with BTZ (20 nM), and 
expression of ubiquitinated proteins was analyzed by immunoblotting. (F) Expression of PSMβ5 
in parental and resistant cells was determined by RT-qPCR (∆∆p<0.01).   
 
Figure 2. Bortezomib-resistant NCI-H929 cells show higher α4β1 expression and function 
than parental cells. (A) CD138+ primary BM myeloma cells incubated for 48 h without (-) or 
with (+) BTZ (20 nM) were tested by RT-qPCR to determine ITGA4 and ITGB1 expression 
(n=3-4; *p<0.05). (B, left) Parental and BTZ-resistant NCI-H929 cells were incubated as in (A), 
and subsequently subjected to flow cytometry for detection of the indicated surface markers. 
Data show fold-induction of fluorescence intensity values referred to parental cells that were 
given a value of 100 (n=5; ∆p<0.05). (Right) Shown are representative histograms for α4 and β1 
expression in parental and resistant cells. (C) Cells were treated with or without BTZ (20 nM) 
and analyzed by immunoblotting to test for α4 and β1 expression. (D) Cells were analyzed by 
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RT-qPCR to determine ITGA4, ITGB1 and CXCR4 expression (n=4; ∆∆p<0.01, ∆p<0.05). (E) 
Cells were subjected to adhesion assays to the indicated α4β1 ligands coimmobilized without 
(Medium) or with CXCL12 (n=3-4; ∆∆p<0.01, ∆p<0.05). (F) Cells were incubated in the absence 
or presence of CXCL12, and the binding of VCAM-1-Fc was determined by flow cytometry 
(n=3; ∆∆∆p<0.001, ∆∆p<0.01). 
 
Figure 3. Bortezomib-resistant RPMI-8226 myeloma cells show higher α4β1 expression 
than parental cells. (A, left) Cells were incubated for 48 h without (-) or with (+) BTZ (7 or 
100 nM), and afterwards subjected to flow cytometry for detection of the indicated markers. 
Data display fold induction of fluorescence intensity values relative to parental cells that were 
given a value of 100 (n=5; ∆∆∆p<0.001, ∆∆p<0.01 and ∆p<0.05). (Right) Shown are 
representative histograms for α4 and β1 expression in parental and resistant cells. (B) Cells 
were treated with or without BTZ and analyzed by immunoblotting for α4 and β1 expression. 
(C) Cells were cultured for 3 weeks in the absence (-) or presence (+) of BTZ (7 or 100 nM), 
and subsequently treated with or without the inhibitor and the α4 and β1 expression was 
analyzed by western blotting. (D) Cells were subjected to qPCR to determine ITGA4, ITGB1 
and CXCR4 expression (n=4-6; ∆∆∆p<0.001, ∆∆p<0.01 and ∆p<0.05). (E) Cells were exposed to 
cycloheximide (CHX; 100 µg/ml) for the indicated times and then tested by immunoblotting.  
 
Figure 4. Bortezomib-resistant RPMI-8226 cells show higher in vitro and in vivo α4β1 
function than parental cells. (A) Cells were subjected to adhesion assays to the indicated α4β1 
ligands coimmobilized with CXCL12 (n=3; ∆p<0.05). (B, left) Parental and BTZ-resistant 
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RPMI-8226 cells were intravenously inoculated into NSG mice, which were treated every 2 
days with control or anti-α4 antibodies. Data represent percentages of myeloma cell infiltration 
in the BM as assessed by HLA+ human expression using flow cytometry. (Right) The expression 
of α4 on the BM infiltrated MM cells was analyzed by flow cytometry (n=7-9 bone marrow 
analyses). Bone marrow infiltration was significantly increased, ∆∆∆p<0.001, or decreased, 
***p<0.001. (C) Myeloma cell infiltration in the BM of NSG mice was determined by RT-qPCR 
measuring the ratio of human GAPDH versus mouse Tbp expression (n=7-8; ∆∆∆p<0.001).  
 
Figure 5. Role of NF-κB in upregulated α4β1 expression and function on BTZ-resistant 
MM cells. (A) Cells incubated without (-) or with BTZ (20 nM, 48 h) were analyzed by 
immunoblotting to test for expression of the indicated proteins. (B) Cells were analyzed by RT-
qPCR for expression of the NF-κB targets BIRC5 and HIF1A (n=3; ∆∆p<0.01, ∆∆∆p<0.001). (C) 
Cells were incubated for 24 h in the absence or presence of BAY-11-7082 (10 µM), and 
expression of ITGA4, ITGB1 and BIRC5 was determined by RT-qPCR (n=2; ***p<0.001, 
*p<0.05). (D) Cells were nucleofected with the indicated siRNA, and expression of NF-κB1 
(left) and ITGA4 (right) was tested by RT-qPCR (n=2-3; **p<0.01, *p<0.05). (E, left) siRNA-
silenced cells were subjected to flow cytometry for detection of cell membrane α4 expression. 
Data show fold induction of fluorescence intensity values referred to control siRNA 
transfectants that were given a value of 100 (n=5; ***p<0.001). (Right) Transfectants were 
subjected to adhesion assays to CS-1/FN (n=3; *p<0.05). 
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Figure 6. Prognostic value of ITGB1 expression in MM. Correlation between the levels of 
ITGB1 expression at diagnosis and progression-free survival (A), and overall survival (B) of 
BTZ/IMIDs-treated patients in the MMRF CoMMpass Study dataset. Kaplan–Meier curves 
represent a bi-level state expression (high and low) of ITGB1. (C, D) Multivariate analysis of 
synergy between ITGB1 and high-risk genetic factors displaying Progression-Free Survival (C) 
and Overall Survival results (D). Kaplan–Meier curves showing the combined study of Amp1q 
and expression levels of ITGB1 for Progression-Free Survival (E), and Overall Survival (F) of 
MM patients from the CoMMpass Study. (Low=Low expression of the ITGB1; High=High 
expression of the ITGB1). 
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